Home Tags Sanofi

Dupilumab Lowered IgE Levels in Small Study

Dave Bloom - 2025/03/17 0

Study Finds Biologic Drug Highly Effective in Reducing Pediatric Eczema Symptoms

News Wire ~ 3rd Party Press Release - 2022/09/19 0

Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11...

News Wire ~ 3rd Party Press Release - 2022/07/15 0

FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12...

News Wire ~ 3rd Party Press Release - 2022/04/12 0

Sanofi Presses Court Battle with Mylan in Appeal of EpiPen Antitrust...

Dave Bloom - 2021/06/07 0

FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...

News Wire ~ 3rd Party Press Release - 2020/05/28 0

Sanofi Seeking Billions from Mylan in EpiPen Antitrust Suit

Dave Bloom - 2019/08/13 0

FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

News Wire ~ 3rd Party Press Release - 2019/03/12 0

Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...

News Wire ~ 3rd Party Press Release - 2018/10/15 0

Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...

Dave Bloom - 2018/09/27 1

12 3 4 Page 1 of 4

Put Your School on the Map

Dave Bloom - 2024/07/31 0

Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.

We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.

Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.

Please see our Terms of Service and Privacy Policy.

Tag: Sanofi